Item 1.01 Entry into a Definitive Material Agreement.
On October 14, 2022, Surmodics, Inc. entered into a secured
revolving credit facility and secured term loan facilities pursuant to a. | October 17, 2022
On
April 15, 2021,
Relay Therapeutics, Inc. (the Company ) entered into an
Agreement and Plan of Merger (the Merger Agreement ) by and among the Company,
Elixir Merger Sub I, Inc., a
Delaware corporation and a wholly-owned direct
subsidiary of the Company ( First Merger Sub ),
Elixir Merger Sub II, LLC, a
Delaware limited liability company and a wholly-owned direct subsidiary of the
Company ( Second Merger Sub and together with First Merger Sub, the Merger
Subs ),
ZebiAI Therapeutics, Inc., a
Shareholder Representative Services LLC, a
Colorado limited liability company,
solely in its capacity as the representative of the ZebiAI Holders (as defined
below). Subject to the satisfaction or waiver of the conditions set forth in the